Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Non-Current Assets (2018 - 2025)

AVITA Medical filings provide 8 years of Non-Current Assets readings, the most recent being $20.9 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 7.97% to $20.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $86.7 million, a 31.21% increase, with the full-year FY2025 number at $20.9 million, down 7.97% from a year prior.
  • Non-Current Assets hit $20.9 million in Q4 2025 for AVITA Medical, down from $22.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $24.0 million in Q3 2021 to a low of $4.2 million in Q2 2021.
  • Median Non-Current Assets over the past 5 years was $13.1 million (2024), compared with a mean of $14.4 million.
  • Biggest five-year swings in Non-Current Assets: surged 519.53% in 2021 and later crashed 65.84% in 2022.
  • AVITA Medical's Non-Current Assets stood at $23.9 million in 2021, then crashed by 54.75% to $10.8 million in 2022, then dropped by 29.35% to $7.6 million in 2023, then surged by 197.5% to $22.7 million in 2024, then fell by 7.97% to $20.9 million in 2025.
  • The last three reported values for Non-Current Assets were $20.9 million (Q4 2025), $22.4 million (Q3 2025), and $21.9 million (Q2 2025) per Business Quant data.